RESUMO
Monoamine oxidase B (MAO-B) inhibitors are used to control Parkinson's disease (PD). Selegiline, rasagiline, and safinamide are widely used as MAO-B inhibitors worldwide. Although these drugs inhibit MAO-B, there are pharmacological and chemical differences, such as the inhibitory activity, the non-dopaminergic properties in safinamide, and the amphetamine-like structure in selegiline. MAO-B inhibitors may differ in adverse events (AEs). However, differences in actual practical clinics are not fully investigated. A retrospective study was conducted using FAERS, the largest database of spontaneous adverse events. AE signals for MAO-B inhibitors, including selegiline, rasagiline, and safinamide, were detected using the reporting odds ratio method and compared. Hypocomplementemia, hepatic cyst, hepatic function abnormal, liver disorder and cholangitis were detected for selegiline as drug-specific signals. The amphetamine effect was not confirmed for any of the three MAO-B inhibitors. The tyramine reaction was detected as an AE signal only for rasagiline. Moreover, the REM sleep behavior disorder was not detected as an AE signal for safinamide, suggesting that non-dopaminergic effects might be beneficial. Considering the differences in AEs for MAO-B inhibitors will assist with the appropriate PD medication.
Assuntos
Inibidores da Monoaminoxidase , Doença de Parkinson , Humanos , Inibidores da Monoaminoxidase/efeitos adversos , Doença de Parkinson/tratamento farmacológico , Selegilina/efeitos adversos , Estudos Retrospectivos , Monoaminoxidase , Dopaminérgicos/uso terapêutico , AnfetaminasRESUMO
Selegiline is an irreversible, selective type-B monoamine oxidase inhibitor (MAOI) approved for Parkison's disease-oral and major depressive disorder-transdermal formulation) resulting in non-selective MAOI activity at oral doses≥20 mg/day. The present systematic review and meta-analysis appraises the evidence of different formulations/dosages of selegiline across different psychiatric conditions. We inquired PubMed/MEDLINE/Cochrane-Central/WHO-ICTRP/Clarivate-WebOfScience and the Chinese-Electronic-Journal Database from inception to 10/26/2022 for selegiline trials involving psychiatric patients. Random-effects meta-analyses assessed heterogeneity, publication/risk biases, and confidence in the evidence, followed by sensitivity, subgroup, and meta-regression analyses. Co-primary outcomes were: changes in symptom score (standardized mean difference=SMD) and author-defined response (risk ratios=RRs). RRs of adverse events and all-cause discontinuation were secondary and acceptability outcomes, respectively. Systematic-review included 42 studies; meta-analysis, 23. Selegiline outperformed placebo in depressive symptom reduction (SMD=-0.96, 95%C.I.=-1.78, -0.14, k = 10, n = 1,308), depression (RR=1.61, 95%C.I.=1.20, 2.15, k = 9, n = 1,238) and atypical-depression response (RR=2.23, 95%C.I.=1.35, 3.68, k = 3, n = 136). Selegiline failed to outperform the placebo in negative (k = 4) or positive symptoms of schizophrenia (k = 4), attention-deficit-hyperactivity disorder (ADHD) symptoms reduction (k = 2), and smoking abstinence rate (k = 4). Selegiline did not differ from methylphenidate and ADHD scores (k = 2). No significant difference emerged in acceptability, incident diarrhea, headache, dizziness, and nausea RRs, in contrast to xerostomia (RR=1.58, 95%C.I. =1.03, 2.43, k = 6, n = 1,134), insomnia (RR=1.61, 95%C.I.=1.19, 2.17, k = 10, n = 1,768), and application-site reaction for transdermal formulation (RR=1.81, 95%C.I.=1.40, 2.33, k = 6, n = 1,662). Confidence in findings was low/very-low for most outcomes; moderate for depressive symptoms reduction (transdermal). Selegiline proved effective, safe, and well-tolerated for depressive disorders, yet further evidence is warranted about specific psychiatric disorders.
Assuntos
Transtorno do Deficit de Atenção com Hiperatividade , Transtorno Depressivo Maior , Metilfenidato , Humanos , Selegilina/efeitos adversos , Transtorno Depressivo Maior/tratamento farmacológico , Inibidores da Monoaminoxidase/efeitos adversos , Transtorno do Deficit de Atenção com Hiperatividade/tratamento farmacológico , Metilfenidato/uso terapêuticoRESUMO
Some brain diseases are associated with oxidative stress and altered monoamine oxidase (MAO) activity. The objective of this study was to evaluate the antioxidant and neuroprotective actions through MAO inhibition of 3-(pyridin-2-yl)-2-(pyridine-2-ylimino) thiazolidin-4-one (PPIT, a synthetic molecule containing a thiazolidinone nucleus), as well as its effects on toxicity parameters in Swiss female mice. Five in vitro assays were carried out to verify the PPIT antioxidant capacity: protein carbonylation (PC), 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) (ABTS), 1,1-diphenyl-2-picryl-hydrazil (DPPH), ferric ion (Fe3+ ) reducing antioxidant power (FRAP), and superoxide dismutase (SOD)-like activity. The results showed that PPIT reduced the level of PC in the homogenate of the brain. This compound did not demonstrate SOD mimetic activity, but it acted as a free radical scavenger (ABTS and DPPH) and exhibited reducing activity in the FRAP assay. In addition, the effects of PPIT on cerebral MAO activity (MAO-A and B isoforms) were investigated in vitro. Our data revealed inhibition of the MAO-B activity by PPIT with no effects on MAO-A. Lastly, an acute oral toxicity test was conducted in mice. No changes in food intake, body weight, and biochemical markers of kidney and liver damage were detected in mice treated with a high dose of PPIT (300 mg/kg). In conclusion, the present study demonstrated that PPIT exhibits antioxidant activity and selectively inhibits the MAO-B isoform without causing apparent toxicity. These findings suggest PPIT as a potential therapeutic candidate to be tested in preclinical models of brain diseases involving perturbations of MAO-B activity and redox status.
Assuntos
Encéfalo/enzimologia , Sequestradores de Radicais Livres/farmacologia , Inibidores da Monoaminoxidase/farmacologia , Monoaminoxidase/metabolismo , Animais , Encefalopatias/tratamento farmacológico , Encefalopatias/enzimologia , Feminino , Sequestradores de Radicais Livres/efeitos adversos , Sequestradores de Radicais Livres/síntese química , Sequestradores de Radicais Livres/química , Masculino , Camundongos , Inibidores da Monoaminoxidase/efeitos adversos , Inibidores da Monoaminoxidase/síntese química , Inibidores da Monoaminoxidase/químicaRESUMO
OBJECTIVE: To review the symptoms of serotonin toxicity (commonly referred to as serotonin syndrome) and the causative drugs and their mechanisms of action, and to equip primary care providers with practical strategies to prevent and identify serotonin toxicity. QUALITY OF EVIDENCE: PubMed and Google Scholar were searched for relevant articles on serotonin toxicity, the causes, and the differential diagnosis using search terms related to serotonin toxicity (serotonin syndrome, serotonin toxicity, serotonin overdose), causes (individual names of drug classes, individual drug names), and diagnosis (differential diagnosis, neuroleptic malignant syndrome, anticholinergic toxicity, discontinuation syndrome, malignant hyperthermia, serotonin symptoms). Experts in psychiatric medicine, psychiatric pharmacy, clinical pharmacology, and medical toxicology were consulted. Evidence is level II and III. MAIN MESSAGE: Serotonin toxicity is a drug-induced condition caused by too much serotonin in synapses in the brain. Cases requiring hospitalization are rare, and mild cases caused by serotonin-mediated side effects are unlikely to be fatal. Patients present with a combination of neuromuscular, autonomic, and mental status symptoms. Serotonin-elevating drugs include monoamine oxidase inhibitors, serotonin reuptake inhibitors, and serotonin releasers. Most cases involve 2 drugs that increase serotonin in different ways; the most concerning combination is a monoamine oxidase inhibitor with a selective serotonin reuptake inhibitor or a serotonin-norepinephrine reuptake inhibitor. CONCLUSION: Family physicians play a key role in identifying and preventing serotonin syndrome by teaching patients to recognize symptoms and monitoring patients throughout therapy.
Assuntos
Papel do Médico , Síndrome da Serotonina/diagnóstico , Síndrome da Serotonina/prevenção & controle , Serotonina/toxicidade , Interações Medicamentosas , Overdose de Drogas/diagnóstico , Overdose de Drogas/terapia , Medicina de Família e Comunidade/educação , Humanos , Inibidores da Monoaminoxidase/efeitos adversos , Inibidores Seletivos de Recaptação de Serotonina/efeitos adversosRESUMO
Monoamine oxidase inhibitors (MAOIs) are known to cause hypertensive crisis when combined with intake of tyramine, classically found in cheese. We present a case of MAOI-induced hypertensive crisis leading to significant troponin release after soft cheese intake. A 51-year-old lady presented with left-sided chest pain, palpitations and headache in the context of significant hypertension after eating soft cheese. She had a similar episode 2 month prior to this presentation, which resulted in a diagnosis of non-ST elevation myocardial infarction after a troponin of 2768 ng/L (Ref < 17 ng/L) with normal cardiac investigations and CT pulmonary angiogram. She was known to be on tranylcypromine for bipolar depression. Subsequent cardiac investigations were normal, as were those for phaeochromocytoma and Conn's disease. Tranylcypromine is a non-selective irreversible MAOI used in refractory depression and bipolar disorder. MAOIs are known to cause hypertensive crisis when combined with soft cheese due to unopposed release of catecholamines from reduced tyramine metabolisation, leading to injury and possible myonecrosis. Three previous case reports have demonstrated either creatinine kinase or troponin rise with myocardial infarction due to this hypertensive crisis and our case is the fourth with significant hypertension and cardiac biomarker rise related to MAOI, specifically tranylcypromine.
Assuntos
Pressão Sanguínea/efeitos dos fármacos , Queijo/efeitos adversos , Cardiopatias/induzido quimicamente , Hipertensão/induzido quimicamente , Inibidores da Monoaminoxidase/efeitos adversos , Miocárdio/patologia , Tranilcipromina/efeitos adversos , Tiramina/efeitos adversos , Anti-Hipertensivos/uso terapêutico , Cardiotoxicidade , Eletrocardiografia , Feminino , Cardiopatias/tratamento farmacológico , Cardiopatias/patologia , Humanos , Hipertensão/diagnóstico , Hipertensão/tratamento farmacológico , Hipertensão/fisiopatologia , Pessoa de Meia-Idade , Necrose , Inibidores da Agregação Plaquetária/uso terapêutico , Fatores de Risco , Resultado do TratamentoRESUMO
El uso de antidepresivos en el perioperatorio es muy frecuente, y la práctica clínica indica que los pacientes usuarios de antidepresivos que son sometidos a cirugía tienen un riesgo perioperatorio aumentado. No existen en la actualidad guías clínicas basadas en la evidencia que orienten el manejo de este tipo de pacientes, por lo que las recomendaciones se basan en las escasas revisiones sistemáticas y metaanálisis disponibles, reportes de casos y opinión de expertos, que en muchos casos resultan controversiales. La decisión de mantener o suspender la medicación antidepresiva implica considerar los riesgos tanto desde el punto de vista fisiológico (características generales del paciente, riesgos asociados al antidepresivo utilizado, la cirugía propiamente como tal, la interacción con fármacos frecuentemente utilizados en el perioperatorio, entre otros) como desde el punto de vista psiquiátrico (riesgo de síndrome de retirada, recaída de la enfermedad psiquiátrica, intentos suicidas), por lo que la decisión debe ser tomada idealmente de forma multidisciplinaria entre cirujanos, anestesiólogos y psiquiatras, con la idea de confeccionar un plan quirúrgico, anestésico y de manejo perioperatorio seguro para el paciente.
Antidepressant use in the perioperative is a common practice, and clinical evidence shows that surgical patients using antidepressants have an increased perioperative risk. There are not evidence-based guidelines for the perioperative management of these patients, and recommendations are based on few systematic reviews and meta-analysis, case reports and expert opinion, which in many cases are controversial. The decision to continue or discontinue the medication involves considering general patient characteristics, risks associated with the antidepressant used, type of surgery, interaction with drugs commonly used in the perioperative, risk of withdrawal symptoms, relapse of psychiatric disease and suicide risk, so decision should be made between surgeons, anesthesiologists and psychiatrists, in order to design a safe management plan for the patient who undergo surgery.
Assuntos
Humanos , Transtorno Depressivo/tratamento farmacológico , Período Perioperatório , Antidepressivos/efeitos adversos , Inibidores Seletivos de Recaptação de Serotonina/efeitos adversos , Inibidores da Monoaminoxidase/efeitos adversos , Antidepressivos Tricíclicos/efeitos adversosRESUMO
BACKGROUND: Experimental evidence indicates that serotonin is associated with both proliferative and pro-carcinogenic effects on colorectal tumors. The present study aims to investigate the associations between antidepressant use and colorectal cancer in an epidemiological sample. METHODS: We conducted a population-based case-control study utilizing Taiwan's National Health Insurance Research Database (NHIRD). We identified 49,342 cases with colorectal cancer and 240,985 controls between 1997 and 2008. We conducted conditional logistic regression analyses to assess the association between antidepressant use and colorectal cancer risk. Sensitivity analyses were conducted to assess whether genotoxic antidepressants (i.e. antidepressants which may exert procarcinogenic effects) would increase risk for colorectal cancer. RESULTS: Selective serotonin reuptake inhibitors (adjusted OR=1.00, 95% CI=0.94-1.06), tricyclic antidepressants, serotonin-norepinephrine reuptake inhibitors, and serotonin antagonist and reuptake inhibitors were not associated with increased incidence of colorectal cancer. Monoamine oxidase inhibitors were, however, associated with an increased incidence of colorectal cancer (adjusted OR=1.22, 95% CI=1.06-1.41). Higher cumulative dose of mirtazapine was associated with a decreased incidence of colorectal cancer (adjusted OR=0.39, 95% CI=0.17-0.90). A small sample size of individuals who received mirtazapine, however, precludes definitive conclusions regarding protective effects with mirtazapine. LIMITATIONS: We could not discern the effects of obesity and other risk factors for colorectal cancer from the NHIRD. CONCLUSIONS: Contemporary first-line antidepressants (i.e. SSRI, SNRI), as well as older agents (i.e. TCA), are not associated with increased incidence of colorectal cancer.
Assuntos
Antidepressivos Tricíclicos/efeitos adversos , Antidepressivos/efeitos adversos , Neoplasias Colorretais/induzido quimicamente , Inibidores da Monoaminoxidase/efeitos adversos , Inibidores Seletivos de Recaptação de Serotonina/efeitos adversos , Idoso , Antidepressivos/uso terapêutico , Antidepressivos Tricíclicos/uso terapêutico , Estudos de Casos e Controles , Neoplasias Colorretais/epidemiologia , Bases de Dados Factuais , Feminino , Humanos , Incidência , Masculino , Pessoa de Meia-Idade , Inibidores da Monoaminoxidase/uso terapêutico , Fatores de Risco , Inibidores Seletivos de Recaptação de Serotonina/uso terapêutico , Taiwan/epidemiologiaRESUMO
INTRODUCTION: Pheochromocytoma is suggested by the presence of severe and paroxysmal hypertension associated with hyperadrenergy clinical signs. If the diagnosis of pheochromocytoma is ruled out, a pseudo-pheochromocytoma should be considered. We report a clinical observation of pseudo-pheochromocytoma due to iproniazid, a non-selective irreversible monoamine oxidase (MAO) A and B inhibitor in a patient with bipolar disorder. CASE REPORT: A 78-year-old Caucasian male patient treated by iproniazid was hospitalized for depressive relapse. After several episodes of syncopes related to orthostatic hypotension, the patient presented hypertensive crisis. Urinary normetanephrines were increased to twice the upper limit of the normal range. Iproniazid was discontinued. Patient hemodynamic was rapidly stabilized and sympathetic hypertonia diminished. The urinary measurements normalized within two months. The abdominal imaging eliminated an adrenal tumor. CONCLUSION: Iproniazid could be responsible for severe irregular blood pressure associated with abnormal catecholamine metabolism (i.e. pseudo-pheochromocytoma).
Assuntos
Neoplasias das Glândulas Suprarrenais/induzido quimicamente , Iproniazida/efeitos adversos , Inibidores da Monoaminoxidase/efeitos adversos , Feocromocitoma/induzido quimicamente , Idoso , Humanos , MasculinoRESUMO
Serotonin syndrome is a potentially life-threatening condition caused by excessive central and peripheral stimulation of serotonin brainstem receptors, usually triggered by inadvertent interactions between agents with serotonergic activity. Evidence supporting an association between nonserotonergic opiates, such as oxycodone or morphine, and serotonin syndrome is very limited and even contradictory. In this case report, we describe a patient who developed serotonergic-adverse effects likely precipitated by an interaction between morphine and phenelzine. A 57-year-old woman presented to the emergency department with complaints of increasing visual hallucinations, restlessness, photophobia, dizziness, neck stiffness, occipital headache, confusion, sweating, tachycardia, and nausea over the previous week. On admission, her blood pressure was 185/65 mm Hg, and clonus was noted in the lower extremities. The patient was hospitalized 10 days earlier for cellulitis of the left breast secondary to a left mastectomy 5 months earlier, and a short course of oral morphine was prescribed for pain control. Her routine medications consisted of aspirin, atorvastatin, bisoprolol, clopidogrel, gabapentin, omeprazole, phenelzine, and ramipril. Supportive measures were initiated on admission. Phenelzine and morphine were discontinued immediately, leading to a progressive resolution of symptoms over the next 48 hours. Phenelzine was restarted on discharge without further complications. Use of the Drug Interaction Probability Scale indicated a probable relationship (score of 6) between the patient's development of serotonin syndrome and the combination of morphine and phenelzine. The mechanism underlying this interaction, however, remains unclear and warrants further investigation. Clinicians should carefully weigh the risk and benefits of initiating morphine in patients taking monoamine oxidase inhibitors or any other serotonin-enhancing drugs.
Assuntos
Analgésicos Opioides/efeitos adversos , Inibidores da Monoaminoxidase/efeitos adversos , Morfina/efeitos adversos , Fenelzina/efeitos adversos , Síndrome da Serotonina/induzido quimicamente , Interações Medicamentosas , Feminino , Humanos , Pessoa de Meia-IdadeRESUMO
The pathological processes underlying Parkinson's disease (PD) involve more than dopamine cell loss within the midbrain. These non-dopaminergic neurotransmitters include noradrenergic, serotonergic, glutamatergic, and cholinergic systems within cortical, brainstem and basal ganglia regions. Several non-dopaminergic treatments are now in clinical use to treat motor symptoms of PD, or are being evaluated as potential therapies. Agents for symptomatic monotherapy and as adjunct to dopaminergic therapies for motor symptoms include adenosine A2A antagonists and the mixed monoamine-B inhibitor (MAO-BI) and glutamate release agent safinamide. The largest area of potential use for non-dopaminergic drugs is as add-on therapy for motor fluctuations. Thus adenosine A2A antagonists, safinamide, and the antiepileptic agent zonisamide can extend the duration of action of levodopa. To reduce levodopa-induced dyskinesia, drugs that target overactive glutamatergic neurotransmission can be used, and include the non-selective N-methyl D-aspartate antagonist amantadine. More recently, selective metabotropic glutamate receptor (mGluR5) antagonists are being evaluated in phase II randomized controlled trials. Serotonergic agents acting as 5-HT2A/2C antagonists, such as the atypical antipsychotic clozapine, may also reduce dyskinesia. 5-HT1A agonists theoretically can reduce dyskinesia, but in practice, may also worsen PD motor symptoms, and so clinical applicability has not yet been shown. Noradrenergic α2A antagonism using fipamezole can potentially reduce dyskinesia. Several non-dopaminergic agents have also been investigated to reduce non-levodopa-responsive motor symptoms such as gait and tremor. Thus the cholinesterase inhibitor donepezil showed mild benefit in gait, while the predominantly noradrenergic re-uptake inhibitor methylphenidate had conflicting results in advanced PD subjects. Tremor in PD may respond to muscarinic M4 cholinergic antagonists (anticholinergics), but tolerability is often poor. Alternatives include ß-adrenergic antagonists such as propranolol. Other options include 5-HT2A antagonists, and drugs that have mixed binding properties involving serotonin and acetylcholine, such as clozapine and the antidepressant mirtazapine, can be effective in reducing PD tremor. Many other non-dopaminergic agents are in preclinical and phase I/II early stages of study, and the reader is directed to recent reviews. While levodopa remains the most effective agent to treat motor symptoms in PD, the overall approach to using non-dopaminergic drugs in PD is to reduce reliance on levodopa and to target non-levodopa-responsive symptoms.
Assuntos
Antiparkinsonianos/uso terapêutico , Transtornos Neurológicos da Marcha/prevenção & controle , Terapia de Alvo Molecular , Neurônios/efeitos dos fármacos , Doença de Parkinson/tratamento farmacológico , Antagonistas da Serotonina/uso terapêutico , Tremor/prevenção & controle , Antagonistas do Receptor A2 de Adenosina/efeitos adversos , Antagonistas do Receptor A2 de Adenosina/uso terapêutico , Animais , Antiparkinsonianos/efeitos adversos , Dopaminérgicos/efeitos adversos , Resistência a Medicamentos , Discinesia Induzida por Medicamentos/tratamento farmacológico , Discinesia Induzida por Medicamentos/metabolismo , Discinesia Induzida por Medicamentos/prevenção & controle , Transtornos Neurológicos da Marcha/etiologia , Humanos , Levodopa/efeitos adversos , Mesencéfalo/efeitos dos fármacos , Mesencéfalo/metabolismo , Inibidores da Monoaminoxidase/efeitos adversos , Inibidores da Monoaminoxidase/uso terapêutico , Neurônios/metabolismo , Uso Off-Label , Doença de Parkinson/metabolismo , Doença de Parkinson/fisiopatologia , Antagonistas da Serotonina/efeitos adversos , Tremor/etiologiaAssuntos
Acetamidas/efeitos adversos , Antibacterianos/efeitos adversos , Inibidores da Monoaminoxidase/efeitos adversos , Oxazolidinonas/efeitos adversos , Propilaminas/efeitos adversos , Acetamidas/uso terapêutico , Antibacterianos/uso terapêutico , Cloridrato de Atomoxetina , Transtorno do Deficit de Atenção com Hiperatividade/complicações , Transtorno do Deficit de Atenção com Hiperatividade/tratamento farmacológico , Infecções Bacterianas/tratamento farmacológico , Infecções Bacterianas/etiologia , Criança , Fibrose Cística/complicações , Interações Medicamentosas , Feminino , Humanos , Linezolida , Inibidores da Monoaminoxidase/uso terapêutico , Oxazolidinonas/uso terapêutico , Propilaminas/uso terapêutico , Escarro/microbiologiaRESUMO
Monoamine oxidase inhibitors (MAOIs) are effective treatments for depression that has atypical features or that has failed to respond to other antidepressants. However, MAOIs are underused because clinicians are concerned about dietary and drug interactions with this class of medication. Hypertensive crisis and serotonin syndrome can occur in rare cases due to interactions between MAOIs and foods containing tyramine as well as interactions with serotonergic and sympathomimetic agents. A better understanding of the foods and drugs that can cause adverse reactions, as well as knowledge of newer MAOIs with mechanisms of action and delivery methods that reduce these risks, may help clinicians to consider the use of these medications, when appropriate, in their patients with depression.
Assuntos
Antidepressivos/efeitos adversos , Transtorno Depressivo/tratamento farmacológico , Interações Alimento-Droga , Inibidores da Monoaminoxidase/efeitos adversos , Administração Cutânea , Administração Oral , Antidepressivos/administração & dosagem , Transtorno Depressivo/diagnóstico , Transtorno Depressivo/psicologia , Transtorno Depressivo Resistente a Tratamento/diagnóstico , Transtorno Depressivo Resistente a Tratamento/tratamento farmacológico , Transtorno Depressivo Resistente a Tratamento/psicologia , Interações Medicamentosas , Humanos , Hipertensão Maligna/induzido quimicamente , Inibidores da Monoaminoxidase/administração & dosagem , Serotoninérgicos/administração & dosagem , Serotoninérgicos/efeitos adversos , Síndrome da Serotonina/diagnóstico , Síndrome da Serotonina/etiologia , Simpatomiméticos/administração & dosagem , Simpatomiméticos/efeitos adversos , Tiramina/administração & dosagem , Tiramina/efeitos adversosRESUMO
Monoamine oxidase inhibitors (MAOIs) were once widely used as effective treatments for major depressive disorder, particularly for patients with atypical or treatment-resistant depression. Today, MAOIs have largely been replaced by newer antidepressants because of concerns over potential serious side effects due to their mechanism of action. Monoamine oxidase (MAO) is an enzyme that metabolizes serotonin, norepinephrine, and dopamine, the neurotransmitters that are most associated with depression; inhibiting MAO, therefore, makes more of these neurotransmitters available for synaptic action. However, MAO also metabolizes tyramine, a trace amine found in some foods that acts as a sympathomimetic. Allowing excess tyramine to accumulate via MAO inhibition can result in hypertensive crisis due to the release of norepinephrine; therefore, patients taking an MAOI have had to follow dietary restrictions to avoid tyramine-rich foods. Hypertensive crisis may also be precipitated by using MAOIs in conjunction with other drugs that have vasoconstrictive properties, that act as sympathomimetics, or that inhibit the reuptake of norepinephrine. Serotonin syndrome is another serious adverse effect that can potentially occur when using an MAOI with another drug that inhibits the reuptake of serotonin. In this article, the mechanism of action of MAOIs is reviewed, along with that of a newer MAOI formulation that lessens the need for dietary restrictions and has a greater safety and tolerability profile than the older oral formulations.
Assuntos
Antidepressivos/administração & dosagem , Transtorno Depressivo/tratamento farmacológico , Interações Alimento-Droga , Inibidores da Monoaminoxidase/administração & dosagem , Administração Cutânea , Antidepressivos/efeitos adversos , Transtorno Depressivo/diagnóstico , Transtorno Depressivo/psicologia , Interações Medicamentosas , Humanos , Hipertensão Maligna/induzido quimicamente , Hipertensão Maligna/diagnóstico , Inibidores da Monoaminoxidase/efeitos adversos , Fatores de Risco , Síndrome da Serotonina/diagnóstico , Síndrome da Serotonina/etiologia , Tiramina/administração & dosagem , Tiramina/efeitos adversosRESUMO
Although primary care clinicians have developed considerable expertise in managing patients with major depressive disorder, and a range of treatment strategies is currently available, some patients still fail to reach remission. Two strategies have fallen out of common use: treating patients with monoamine oxidase inhibitors (MAOIs) and subgrouping patients by diagnosis when selecting antidepressant treatment. Monoamine oxidase inhibitors became less popular because other treatments were perceived to be safer and easier to use. However, a newer transdermal formulation of an MAOI that limits the need for the dietary restrictions of oral MAOIs may make it worthwhile to consider using this class of medication in patients who have failed several treatment trials. Although adverse events due to patients' diets are less likely with the transdermal MAOI, clinicians should still be alert for drug interactions and observe recommended washout periods. Patients who may benefit from MAOI treatment include those with treatment-resistant depression, atypical depression, anxiety, or anergic bipolar depression and those who have experienced intolerable metabolic or sexual side effects with other medications.
Assuntos
Antidepressivos/administração & dosagem , Antidepressivos/efeitos adversos , Transtorno Depressivo/tratamento farmacológico , Inibidores da Monoaminoxidase/administração & dosagem , Inibidores da Monoaminoxidase/efeitos adversos , Atenção Primária à Saúde , Administração Cutânea , Administração Oral , Transtornos de Ansiedade/diagnóstico , Transtornos de Ansiedade/tratamento farmacológico , Transtornos de Ansiedade/psicologia , Transtorno Bipolar/diagnóstico , Transtorno Bipolar/tratamento farmacológico , Transtorno Bipolar/psicologia , Comorbidade , Transtorno Depressivo/diagnóstico , Transtorno Depressivo/psicologia , Transtorno Depressivo Resistente a Tratamento/diagnóstico , Transtorno Depressivo Resistente a Tratamento/tratamento farmacológico , Transtorno Depressivo Resistente a Tratamento/psicologia , Diagnóstico Diferencial , Interações Medicamentosas , Interações Alimento-Droga , Humanos , Hipertensão Maligna/induzido quimicamente , Hipertensão Maligna/diagnóstico , Adesão à Medicação , Educação de Pacientes como Assunto , Síndrome da Serotonina/diagnóstico , Síndrome da Serotonina/etiologiaRESUMO
OBJECTIVE: To investigate the occurrence of intraoperative hemodynamic events when antidepressive treatment with monoamine oxidase inhibitors (MAOIs) was continued during anesthesia. METHOD: A retrospective observational cohort study was conducted among patients who were admitted for elective surgery requiring anesthesia in 8 Dutch hospitals (2004-2010). The index group included current users of irreversible (tranylcypromine) and reversible (moclobemide) MAOIs. The reference group included a sample of nonusers matched to the index group on hospital, type and period of surgery, and type of anesthesia (ratio 1:3). The outcome of interest was the occurrence of the following intraoperative hemodynamic events: hypotension or hypertension and tachycardia or bradycardia. RESULTS: Approximately 280,000 surgical procedures were performed in the participating hospitals in the total observational period of 33 years. The index group included 26 and 25 users of tranylcypromine and moclobemide, respectively. The reference groups included 149 nonusers. Intraoperative hypotension occurred less frequently in users of tranylcypromine (46%) than in nonusers (73%) (P = .01). The occurrence of hypertension, bradycardia, and tachycardia during anesthesia was not different between users of tranylcypromine (27%, 50%, and 12%, respectively) and those in the reference group (35%, 61%, and 26%, respectively). The occurrence of hypotension, hypertension, bradycardia, and tachycardia was not different between users of moclobemide and the reference group. CONCLUSIONS: Severe adverse hemodynamic events, such as hypertension and tachycardia, did not occur more frequently in users of both the irreversible MAOI tranylcypromine and the reversible MAO-A inhibitor moclobemide compared to nonusers. These findings suggest that there is no longer much justification to discontinue these MAOIs before surgery, with the considerable risk of compromising patients' psychiatric status.
Assuntos
Antidepressivos/efeitos adversos , Hemodinâmica/efeitos dos fármacos , Complicações Intraoperatórias/induzido quimicamente , Inibidores da Monoaminoxidase/efeitos adversos , Adulto , Idoso , Antidepressivos/uso terapêutico , Pressão Sanguínea/efeitos dos fármacos , Estudos de Coortes , Feminino , Frequência Cardíaca/efeitos dos fármacos , Humanos , Hipertensão/induzido quimicamente , Masculino , Pessoa de Meia-Idade , Moclobemida/efeitos adversos , Moclobemida/uso terapêutico , Inibidores da Monoaminoxidase/uso terapêutico , Países Baixos , Estudos Retrospectivos , Taquicardia/induzido quimicamente , Tranilcipromina/efeitos adversos , Tranilcipromina/uso terapêuticoRESUMO
Rasagiline is an irreversible monoamine oxidase type B (MAO-B) inhibitor indicated for the treatment of the signs and symptoms of idiopathic Parkinson disease as initial monotherapy and as adjunct therapy to levodopa. Pharmacologic inhibition of monoamine oxidase type A (MAO-A), but not MAO-B, poses a risk of the "cheese effect," a hypertensive response to excess dietary tyramine, a biogenic sympathomimetic amine. Tyramine challenge studies, conducted to characterize rasagiline selectivity for the MAO-B enzyme and tyramine sensitivity, demonstrate that rasagiline, when used at the recommended dose, is selective for MAO-B and is not associated with heightened tyramine sensitivity. This conclusion is also supported by safety results from large clinical trials of rasagiline in Parkinson disease involving 2066 rasagiline-treated patients who did not require dietary tyramine restriction per protocol. In late 2009, US labeling for rasagiline was modified to state that dietary tyramine restrictions are not ordinarily required when rasagiline is administered at recommended doses. In addition, because rasagiline has been demonstrated to be selective for MAO-B at the approved dose of up to 1 mg/d, contraindications regarding concomitant use with sympathomimetic amines, use of sympathomimetic vasopressors in conjunction with general or local anesthesia, and use in patients with pheochromocytoma also were removed.
Assuntos
Antiparkinsonianos/uso terapêutico , Encéfalo/efeitos dos fármacos , Proteínas Alimentares/metabolismo , Indanos/uso terapêutico , Inibidores da Monoaminoxidase/uso terapêutico , Monoaminoxidase/metabolismo , Doença de Parkinson/tratamento farmacológico , Tiramina/metabolismo , Antiparkinsonianos/efeitos adversos , Encéfalo/enzimologia , Proteínas Alimentares/efeitos adversos , Relação Dose-Resposta a Droga , Interações Alimento-Droga , Humanos , Hipertensão/etiologia , Hipertensão/prevenção & controle , Indanos/efeitos adversos , Inibidores da Monoaminoxidase/efeitos adversos , Doença de Parkinson/enzimologia , Segurança do Paciente , Medição de Risco , Fatores de Risco , Resultado do Tratamento , Tiramina/efeitos adversosRESUMO
This article describes the sequence of acute clinical deterioration seen in a head and neck oncology patient who developed serotonin syndrome peri-operatively. It highlights the clinical dilemma that can be encountered when a septic picture masks the onset of serotonin syndrome and reinforces the importance of awareness of the potential interactions and side effects associated with drugs that surgeons prescribe. We discuss the pathophysiology, causal factors, clinical presentation and diagnosis of serotonin syndrome as well as highlighting some of the dilemmas that this condition presents in the surgical setting.
Assuntos
Inibidores da Monoaminoxidase/efeitos adversos , Complicações Pós-Operatórias/induzido quimicamente , Inibidores Seletivos de Recaptação de Serotonina/efeitos adversos , Síndrome da Serotonina/induzido quimicamente , Idoso , Carcinoma de Células Escamosas/cirurgia , Transtorno Depressivo/induzido quimicamente , Transtorno Depressivo/tratamento farmacológico , Diagnóstico Diferencial , Interações Medicamentosas , Febre/induzido quimicamente , Humanos , Masculino , Staphylococcus aureus Resistente à Meticilina , Neoplasias Palatinas/cirurgia , Receptores de Serotonina/fisiologia , Sepse/diagnóstico , Síndrome da Serotonina/diagnóstico , Infecções Estafilocócicas/complicações , Infecções Estafilocócicas/tratamento farmacológicoRESUMO
OBJECTIVE: Depression is the most common psychiatric disease, which is treated by the use of antidepressive agents possessing various mechanisms of action. Thus, the use in preoperative period of antidepressive agents is frequent (7% of patients scheduled for surgery). The objective of this review was to update the knowledge on the drug interactions between antidepressive agents and drugs used in perioperative period. METHODS: (i) Medline and Ovid databases using combination of antidepressive agent and perioperative period as keywords; (ii) national and European epidemiologic database; (iii) expert recommendation and official French health agency; (iv) reference book chapters. RESULTS: The clinical practice showed a limited risk of adverse event related to antidepressant agents interaction with perioperative used drugs. In the two past decades, few relevant observations of adverse event related with imipramine and monoamine oxidase inhibitors use was reported. The most recent antidepressive agents had no serious adverse interaction. Nevertheless, the serotonin syndrome has to be known as far as it is more and more reported. In case of hypotension, the use of vasopressive agent has to be careful because of excessive response.
Assuntos
Antidepressivos/efeitos adversos , Complicações Intraoperatórias/induzido quimicamente , Período Perioperatório , Complicações Pós-Operatórias/induzido quimicamente , Anestésicos/efeitos adversos , Antidepressivos Tricíclicos/efeitos adversos , Interações Medicamentosas , Europa (Continente) , França , Humanos , Inibidores da Monoaminoxidase/efeitos adversos , Sistema Nervoso Parassimpático/efeitos dos fármacos , Risco , Serotonina/fisiologia , Síndrome da Serotonina/complicações , Síndrome de Abstinência a Substâncias/complicações , Síndrome de Abstinência a Substâncias/psicologiaRESUMO
Depression and fibromyalgia syndrome are debilitating chronic conditions that impose a significant burden on individuals, families and society. Both depression and fibromyalgia have many overlapping symptoms, and antidepressants of several classes are among recommended treatment options for patients with fibromyalgia syndrome. Pirlindole is a selective and reversible inhibitor of monoamine oxidase (MAO) subtype A (MAO-A) that is approved in some European and non-European countries for the treatment of depression. The antidepressant efficacy and safety of pirlindole have been demonstrated in a number of placebo- and active comparator-controlled studies and are supported by many years of clinical experience in the treatment of depression. The drug's efficacy and safety have also been demonstrated, more recently, in the treatment of fibromyalgia syndrome. Pirlindole has a favourable tolerability profile, with no deleterious effect on cardiovascular dynamics. The effect of pirlindole on sensorimotor performance relevant to driving a motor vehicle is similar to that of placebo, as pirlindole appears to have an activating rather than a sedating antidepressant profile. Because of its specific and reversible inhibition of MAO-A and relatively short elimination half-life, no tyramine or 'cheese' effect is likely after short- or long-term administration. The available evidence supports pirlindole as a safe and effective treatment option for the management of depression and fibromyalgia syndrome.
Assuntos
Carbazóis/uso terapêutico , Efeitos Psicossociais da Doença , Depressão/tratamento farmacológico , Fibromialgia/tratamento farmacológico , Inibidores da Monoaminoxidase/uso terapêutico , Antidepressivos/efeitos adversos , Antidepressivos/farmacologia , Antidepressivos/uso terapêutico , Carbazóis/efeitos adversos , Carbazóis/farmacologia , Depressão/diagnóstico , Fibromialgia/diagnóstico , Humanos , Inibidores da Monoaminoxidase/efeitos adversos , Inibidores da Monoaminoxidase/farmacologiaRESUMO
OBJECTIVES: Reducing adverse drug events, including those resulting from drug-drug interactions, will be a health safety issue of increasing importance for dental practitioners in the coming decades as greater numbers of older adults seek oral health care. The purpose of this study was to identify prescription drugs with the potential for serious interactions and estimate prevalent use among older adults visiting the dentist. STUDY DESIGN: The Medicare Current Beneficiary Survey is an ongoing series of nationally representative surveys of Medicare beneficiaries. Potentially serious drug interactions were selected with the use of published work by Partnership to Prevent Drug-Drug Interactions. Drug interactions were identified and prevalence estimates made for community-dwelling older adults visiting the dentist. Analyses were completed to test associations between sociodemographic and health-related variables and the use of prescription drugs with the potential for serious interactions. RESULTS: Overall, 3.4% of those visiting the dentist were estimated to have been prescribed drugs with the potential for a serious drug interaction. Drugs commonly prescribed in dentistry with the potential for serious interactions include the benzodiazepines, macrolide antibiotics, and nonsteroidal antiinflammatory analgesics. CONCLUSIONS: Understanding potentially harmful drug combinations, their clinical consequences, and the frequency with which implicated drugs are being prescribed will assist practitioners in clinically managing patients and avoiding inappropriate prescribing.